Ultragenyx Pharmaceutical Inc. - COM (RARE)

Historical Portfolio Holders from Q1 2014 to Q3 2024

All holders as of June 30, 2024
Q2 2024
Type / Class
Equity / COM
Shares, excl. options Q2 2024
88.2M
Holdings value Q2 2024
$3.62B
Value change Q2 2024
+$371M
Grand Portfolio weight change Q2 2024
+0.001%
Number of holders
270
Number of buys Q2 2024
44
Number of sells Q2 2024
-33
Average buys Q2 2024 %
+0%
Average sells Q2 2024 %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Period Shares, Excl. Options Value, Excl. Options Change Price Investors
2024 Q3 5.12M $283M +$9.46M $55.55 94
2024 Q2 88.2M $3.62B +$371M $41.10 270
2024 Q1 79.1M $3.69B -$59.2M $46.69 268
2023 Q4 80.4M $3.84B +$527M $47.82 236
2023 Q3 70M $2.5B -$16.5M $35.65 219
2023 Q2 69.5M $3.2B +$38.3M $46.13 239
2023 Q1 68.7M $2.75B +$28.2M $40.10 226
2022 Q4 68M $3.15B +$13.2M $46.33 223
2022 Q3 67.8M $2.81B -$150M $41.41 223
2022 Q2 67.5M $4.03B +$25.5M $59.66 209
2022 Q1 67M $4.87B -$37.3M $72.62 226
2021 Q4 67.6M $5.68B +$80.5M $84.09 223
2021 Q3 66.6M $6.01B +$98.4M $90.19 216
2021 Q2 65.4M $6.23B -$246M $95.35 232
2021 Q1 67.8M $7.72B +$45.6M $113.86 245
2020 Q4 67.6M $9.36B +$641M $138.43 248
2020 Q3 63.1M $5.19B -$1.96M $82.19 199
2020 Q2 63.1M $4.94B +$243M $78.22 186
2020 Q1 60.1M $2.67B +$88M $44.43 167
2019 Q4 57.9M $2.47B -$30.5M $42.71 161
2019 Q3 58.6M $2.51B -$3.75M $42.78 163
2019 Q2 58.8M $3.73B +$49M $63.50 164
2019 Q1 58.2M $4.04B +$544M $69.36 172
2018 Q4 50.5M $2.2B -$8.45M $43.48 154
2018 Q3 49.8M $3.8B +$72.5M $76.34 170
2018 Q2 48.8M $3.75B +$16.2M $76.87 151
2018 Q1 48.9M $2.5B +$367M $50.99 159
2017 Q4 43.2M $2B +$107M $46.38 155
2017 Q3 40.6M $2.16B -$38.8M $53.26 148
2017 Q2 41.2M $2.55B +$26.7M $62.11 152
2017 Q1 40.7M $2.76B +$156M $67.78 160
2016 Q4 41.5M $2.92B +$147M $70.31 169
2016 Q3 39.5M $2.8B +$175M $70.94 164
2016 Q2 36.4M $1.78B -$46.8M $48.91 152
2016 Q1 36.5M $2.31B +$79.8M $63.31 155
2015 Q4 35.6M $3.99B +$35.7M $112.18 168
2015 Q3 35.3M $3.4B +$264M $96.31 156
2015 Q2 32.4M $3.32B +$100M $102.39 148
2015 Q1 31.6M $1.96B +$227M $62.09 126
2014 Q4 27.9M $1.23B +$59.2M $43.88 99
2014 Q3 26.4M $1.5B +$353M $56.60 98
2014 Q2 15.6M $690M +$13.8M $44.89 80
2014 Q1 15.3M $730M +$730M $48.89 76